Robert F. Sidonio, Jr., MD, MSc

Associate Professor of Pediatrics
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine

Dr. Robert F. Sidonio, Jr. is an Associate Professof of Pediatrics and the Associate Director of Hemostasis and Thrombosis at Emory University in Atlanta, Gerogia. Dr. Sidonio’s clinical and research interest is in investigating the bleeding phenotype and genotype of women with hemophilia carriage and low VWF. He is also the co-creator of the Atlanta Protocol which combines Emicizumab and FVIII for ITI. He is the co-PI of the HOG VWD project focused on characterization of children with low VWF in Atlanta Georgia. He is also the lead PI for the Emicizumab PUP and Nuwiq ITI trial, MOTIVATE study, ATHN 9 study (severe VWD) and FEIBA SAFE study.

Presentation(s):

• SSC 05.12 - SSC Joint Session: Women's Issues in Thrombosis and Hemostasis, Von Willebrand Factor, and Platelet Physiology

  Saturday, July 9, 2022
  2:30 PM – 4:30 PM

• SSC 05.04 - Q&A

  Saturday, July 9, 2022
  3:00 PM – 3:15 PM

• SSC 05.08 - Q&A

  Saturday, July 9, 2022
  3:45 PM – 3:55 PM

• SSC 05.11 - Q&A

  Saturday, July 9, 2022
  4:20 PM – 4:30 PM

• OC 51.6 - Mechanisms of Prothrombotic States in Women’s Health

  Tuesday, July 12, 2022
  10:45 AM – 12:00 PM

• SSC 19.01 - Introduction

  Tuesday, July 12, 2022
  4:30 PM – 4:40 PM

• SSC 19.09 - Q&A

  Tuesday, July 12, 2022
  6:10 PM – 6:25 PM

• SSC 19.10 - Conclusion

  Tuesday, July 12, 2022
  6:25 PM – 6:30 PM

• PB1158 - MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – MOTIVATE (www.motivate-study.com)

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1159 - The Atlanta Study: Emicizumab and simoctocog alfa in previously untreated/minimally treated patients and in patients with inhibitors

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1174 - Eptacog beta for resolution of bleeding episodes in patients with hemophilia A or B with inhibitors: Efficacy and safety according to inhibitor titer

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM